Business Standard

Divi's Labs falls 8% as Q4 profit misses Street estimates

Q4 Ebitda margins were 32.7 per cent against 35.52 per cent in year ago quarter, due to higher raw material price,a weak product mix and higher other expense.

Drugs, Pharma, medicine
Premium

SI Reporter Mumbai
Divi’s Laboratories shares slipped 8 per cent to Rs 1,618 in intra-day trade on the BSE on Monday after the company reported a lower-than-expected 10 per cent year-on-year (YoY) growth in net profit at Rs 289 crore in March quarter (Q4FY19). Total revenue grew 15 per cent at Rs 1,256 crore on YoY basis.

Analysts, on an average, had expected a profit of Rs 382 crore and revenue of Rs 1,326 crore for the quarter.

Q4 Ebitda (earnings before interest, tax, depreciation and amortization) margins came at 32.7 per cent against 35.52 per cent in the year-ago quarter,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in